{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:09:43Z","timestamp":1793120983916,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Sub-Saharan Africa carries the greatest burden of HIV-infection with increasing drug resistance burden, which requires improved patient management and monitoring. Current WHO recommendations suggest transitioning to dolutegravir-based (adults) or raltegravir-based-regimens (neonates) for initial antiretroviral therapy (ART) and as a suitable alternative in cases of multi-resistance in resource-limited settings. This review aims at synthesizing the current knowledge on dolutegravir use and integrase resistance-associated mutations found before the wide use of dolutegravir-based regimens.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This systematic review will include randomized and non-randomized trials, cohort, and cross-sectional studies published on dolutegravir use or integrase resistance-associated mutations in Sub-Saharan Africa. Searches will be conducted (from 2007 onwards) in PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Latin American and Caribbean Health Sciences Literature (LILAC), Web of Science, African Journals Online, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases. Hand searching of the reference lists of relevant reviews and trials will be conducted and we will also look for conference abstracts. We will include studies of adults and\/or children exposed to integrase inhibitors-based therapies; especially dolutegravir or raltegravir (which is our intervention of interest as compared to other antiretroviral regimens). We will exclude studies of patients with specific co-morbidities such as tuberculosis or opportunistic infections. Primary outcomes will be \u201cthe rate of viral suppression\u201d and \u201cthe level of drug resistance\u201d on integrase inhibitor-based regimens among patients in Sub-Saharan Africa. Secondary outcomes will be \u201cthe effect of baseline viremia on viral suppression,\u201d \u201cthe effect of treatment duration on viral suppression,\u201d \u201cthe proportion of patients with immune recovery,\u201d \u201cthe rate of non-adherence,\u201d \u201crate of adverse events;\u201d \u201cdrug resistance according to different integrase inhibitor-based regimens,\u201d and \u201cdrug resistance according to viral subtypes\/recombinants.\u201d Two reviewers will independently screen titles and abstracts, assess the full texts for eligibility, and extract data. If data permits, random effects models will be used where appropriate. Subgroup and additional analyses will be conducted to explore the potential sources of heterogeneity (e.g., age, sex, baseline viremia, CD4 following treatment, treatment duration, and adherence level).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Discussion<\/jats:title>\n<jats:p>This review will help to strengthen evidence on the effectiveness of integrase strand transfer inhibitors by contributing to current knowledge on the use of dolutegravir and\/or raltegravir (especially for neonates) in Sub-Saharan Africa. Results will therefore help in setting-up baseline data for an optimal management of people living with HIV as Sub-Saharan African countries are transitioning to dolutegravir-based regimens. Evidence will also support HIV\/AIDS programs in identifying gaps and actions to be undertaken for improved long-term care and treatment of people living with HIV in Sub-Saharan Africa.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Systematic review registration<\/jats:title>\n<jats:p>PROSPERO CRD42019122424<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13643-020-01356-z","type":"journal-article","created":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T11:02:27Z","timestamp":1587812547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis protocol"],"prefix":"10.1186","volume":"9","author":[{"given":"Ezechiel Ngoufack Jagni","family":"Semengue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Mercedes","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valantine Ngum","family":"Ndze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Dambaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desir\u00e9","family":"Takou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Teto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Durand","family":"Nka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Fabeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Wiyeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Colizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo-Federico","family":"Perno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Fokam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,25]]},"reference":[{"issue":"11","key":"1356_CR1","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3018(16)30091-1","volume":"2016","author":"S Kanters","year":"2016","unstructured":"Kanters S, Vitoria M, Doherty M, Socias ME, Ford N, Forrest JI, et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Lancet HIV [Internet]. 2016;2016(11):e510\u201320 Available from: https:\/\/doi.org\/10.1016\/S2352-3018(16)30091-1.","journal-title":"Lancet HIV [Internet]."},{"key":"1356_CR2","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.meegid.2016.06.047","volume":"46","author":"YS Han","year":"2016","unstructured":"Han YS, Mespl\u00e8de T, Wainberg MA. Differences among HIV-1 subtypes in drug resistance against integrase inhibitors. Infect Genet Evol [Internet]. 2016;46:286\u201391 Available from: https:\/\/doi.org\/10.1016\/j.meegid.2016.06.047.","journal-title":"Infect Genet Evol [Internet]."},{"issue":"2","key":"1356_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40121-014-0029-7","volume":"3","author":"DE Dow","year":"2014","unstructured":"Dow DE, Bartlett JA. Dolutegravir, the second-generation of integrase strand transfer inhibitors (INSTIs) for the treatment of HIV. Infect Dis Ther. 2014;3(2):83\u2013102.","journal-title":"Infect Dis Ther."},{"key":"1356_CR4","doi-asserted-by":"crossref","unstructured":"Daar ES, DeJesus E, Ruane P, Crofoot G, Oguchi G, Creticos C, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48\u2009week results of a randomised, open-label, multicentre, ph. Lancet HIV [Internet]. 2018 Jul [cited 2019 Mar 8];5(7):e347\u201356. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352301818300912.","DOI":"10.1016\/S2352-3018(18)30091-2"},{"key":"1356_CR5","doi-asserted-by":"crossref","unstructured":"Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet [Internet]. 2017 Nov [cited 2019 Mar 8];390(10107):2063\u201372. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673617322997.","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"1356_CR6","doi-asserted-by":"crossref","unstructured":"Fernandez C, van Halsema CL. Evaluating cabotegravir\/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential. Vol. 11, HIV\/AIDS - Research and Palliative Care. Dove Medical Press Ltd.; 2019. p. 179\u201392.","DOI":"10.2147\/HIV.S184642"},{"key":"1356_CR7","doi-asserted-by":"crossref","unstructured":"Jacobson JM, Flexner CW. Universal antiretroviral regimens: thinking beyond one-pill-once-a-day. Vol. 12, Current Opinion in HIV and AIDS. Lippincott Williams and Wilkins; 2017. p. 343\u2013350.","DOI":"10.1097\/COH.0000000000000374"},{"issue":"5","key":"1356_CR8","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1128\/AAC.04844-14","volume":"59","author":"E Akihisa","year":"2015","unstructured":"Akihisa E, Kawauchi-Miki S, Miki S, Sato A, Wakasa-Morimoto C, Fujiwara T, et al. Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro. Antimicrob Agents Chemother. 2015;59(5):2596\u2013606.","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"1356_CR9","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1093\/jac\/dkx475","volume":"73","author":"P Gantner","year":"2018","unstructured":"Gantner P, Lee GQ, Rey D, Mesplede T, Partisani M, Cheneau C, et al. Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs. J Antimicrob Chemother. 2018;73(4):1045\u201353.","journal-title":"J Antimicrob Chemother."},{"key":"1356_CR10","doi-asserted-by":"crossref","unstructured":"Wainberg MA, Han Y-S, Mespl\u00e8de T. Might dolutegravir be part of a functional cure for HIV? Can J Microbiol [Internet]. 2016;62(5):375\u201382. Available from. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27031127.","DOI":"10.1139\/cjm-2015-0725"},{"key":"1356_CR11","unstructured":"World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing hiv infection. 2016;."},{"key":"1356_CR12","doi-asserted-by":"crossref","unstructured":"Molina J-M, Ward D, Brar I, Mills A, Stellbrink H-J, L\u00f3pez-Cort\u00e9s L, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48\u2009week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV [Internet]. 2018 Jul [cited 2019 Mar 8];5(7):e357\u201365. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352301818300924.","DOI":"10.1016\/S2352-3018(18)30092-4"},{"key":"1356_CR13","doi-asserted-by":"crossref","unstructured":"Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink H-JJ, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380\u20131490): a randomised, double-blind, multicentre, phase 3, non-inferiori. Lancet [Internet]. 2017 Nov [cited 2019 Mar 8];390(10107):2073\u201382. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673617323401.","DOI":"10.1016\/S0140-6736(17)32340-1"},{"issue":"5","key":"1356_CR14","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1093\/jac\/dky005","volume":"73","author":"SC Inzaule","year":"2018","unstructured":"Inzaule SC, Hamers RL, Noguera-Julian M, Casadell\u00e0 M, Parera M, de Wit TFR, et al. Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa. J Antimicrob Chemother. 2018;73(5):1167\u201372.","journal-title":"J Antimicrob Chemother."},{"key":"1356_CR15","doi-asserted-by":"crossref","unstructured":"Ndashimye E. High time to start human immunodeficiency virus type 1-infected patients on integrase inhibitors in sub-Saharan Africa. Vol. 216, Journal of Infectious Diseases. 2017. p. 283\u20134.","DOI":"10.1093\/infdis\/jix293"},{"issue":"2","key":"1356_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.14306\/renhyd.20.2.223","volume":"20","author":"D Moher","year":"2016","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Rev Esp Nutr Humana y Diet. 2016;20(2):148\u201360.","journal-title":"Rev Esp Nutr Humana y Diet."},{"key":"1356_CR17","unstructured":"Higgins J, Sally G. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration, editor. John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England Telephone (+44) 1243 779777; 2008. 674 p."},{"key":"1356_CR18","doi-asserted-by":"crossref","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355.","DOI":"10.1136\/bmj.i4919"},{"issue":"October","key":"1356_CR19","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"J Sterne","year":"2016","unstructured":"Sterne J, Hern\u00e1n M, Reeves B, Savovi\u0107 J, Berkman N, Viswanathan M, et al. Risk of bias in non-randomized studies of interventions ( ROBINS-I ): detailed guidance. Bmj. 2016;355(October):i4919.","journal-title":"Bmj."},{"issue":"9","key":"1356_CR20","first-page":"421","volume":"109","author":"J Singh","year":"2018","unstructured":"Singh J, Tugwell P, Wells G, Vecchi S, Davies P, Churchill R, et al. ROBIS: a new tool to assess risk of bias in systematic reviews was developed. Recenti Prog Med. 2018;109(9):421\u201331.","journal-title":"Recenti Prog Med."},{"key":"1356_CR21","unstructured":"Whiting P, Svovic J, Higgins J, Caldwell D, Reeves B, Shea B, et al. ROBIS: tool to assess risk of bias in systematic reviews guidance on how to use ROBIS. Univ Bristol Sch Soc Community Med [Internet]. 2018;1\u201339. Available from: https:\/\/www.bristol.ac.uk\/media-library\/sites\/social-community-medicine\/robis\/robisguidancedocument.pdf%0A, http:\/\/www.bristol.ac.uk\/media-library\/sites\/social-community-medicine\/robis\/robisguidancedocument.pdf."},{"key":"1356_CR22","unstructured":"Guyatt G. et Busse J. Risk of bias in cohort studies | systematic review and literature review software by evidence partners [internet]. Available from: https:\/\/www.evidencepartners.com\/resources\/methodological-resources\/risk-of-bias-in-cohort-studies\/ [Access date: 26\/11\/2019]."},{"key":"1356_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1756-0500-5-52","volume":"5","author":"JL Neyeloff","year":"2012","unstructured":"Neyeloff JL, Fuchs SC, Moreira LB. Meta-analyses and forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC Res Notes. 2012 Jan 20;5:52.","journal-title":"BMC Res Notes."}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-020-01356-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-020-01356-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-020-01356-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T00:00:47Z","timestamp":1619308847000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-020-01356-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,25]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1356"],"URL":"https:\/\/doi.org\/10.1186\/s13643-020-01356-z","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,25]]},"assertion":[{"value":"1 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no existing competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}